Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A compound of [[the]] formula [[I]] I':





wherein

A is ~~C(=OO)R^1~~ C(=O)OR^1, or C(=O)NHSO$_2$R^2, ~~C(=O)NHR^3, or CR^{4}R$^{4'}$~~ wherein;

R^1 is hydrogen, C$_1$-C$_6$alkyl, C$_0$-C$_3$alkylcarbocyclyl, C$_0$-C$_3$alkylheterocyclyl;

R^2 is C$_1$-C$_6$alkyl, C$_0$-C$_3$alkylcarbocyclyl, C$_0$-C$_3$alkylheterocyclyl;

~~R^3 is C$_1$-C$_6$alkyl, C$_0$-C$_3$alkylcarbocyclyl, C$_0$-C$_3$alkylheterocyclyl, -OC$_1$-C$_6$alkyl, -OC$_0$-C$_3$alkylcarbocyclyl, -OC$_0$-C$_3$alkylheterocyclyl;~~

~~R^4 is =O, halo, amino, or OH; or R^4 and R$^{4'}$ together are =O;~~

~~$R^{4'}$ is C_1-C_6alkyl, C_0-C_3alkylcarbocyclyl, C_0-C_3alkylheterocyclyl;~~ wherein

R^2, ~~R^3, and $R^{4'}$ are each~~ is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, oxo, nitrile, azido, nitro, C_1-C_6alkyl, C_0-C_3alkylcarbocyclyl, C_0-C_3alkylheterocyclyl, NH_2CO-, Y-NRaRb, Y-O-R_b, Y-C(=O)Rb, Y-(C=O)NRaRb, Y-NRaC(=O)Rb, Y-$NHSO_p$Rb, Y-$S(=O)_p$Rb ~~and~~ , Y-$S(=O)_p$NRaRb, Y-C(=O)ORb, Y-NRaC(=O)ORb;

Y is independently a bond or C_1-C_3alkyl;

Ra is independently H or C_1-C_3alkyl;

Rb is independently H, C_1-C_6alkyl, C_0-C_3alkylcarbocyclyl or C_0-C_3alkylheterocyclyl;

p is independenly 1 or 2;

M is $CR^7R^{7'}$ ~~or NRu~~;

~~R^7 is C_1-C_6alkyl, C_0-C_3alkylC_3-C_7cycloalkyl, or C_2-C_6alkenyl, any of which is optionally substituted with 1-3 halo atoms, or an amino, -SH, or C_0-C_3alkylcycloalkyl group; or R^7 is J;~~

R^7 ~~is H or~~ taken together with ~~R^7~~ $R^{7'}$ forms a C_3-C_6cycloalkyl ring ~~optionally~~ substituted with ~~$R^{7'a}$ wherein;~~

~~$R^{7'a}$ is C_1-C_6alkyl, C_3-C_5cycloalkyl, C_2-C_6alkenyl any of which may be optionally substituted with halo; or $R^{7'a}$ can be~~ J;

q is ~~0 to 3~~ 1 and k is ~~0 to 3~~ 1; ~~where q+k≥ 1;~~

W is –CH_2-, -O-, -OC(=O)NH, -OC(=O), -S-, –NH-, -NRa, -$NHSO_2$-, -NHC(=O)NH- or –NHC(=O)-, -NHC(=S)NH- or a bond;

R^8 is a ring system containing 1 or 2 saturated, partially saturated or unsaturated rings each of which has 4-7 ring atoms and each of which has 0 to 4 hereto atoms independently selected from S, O and N, the ring system being optionally spaced from W by a C_1-C_3 alkylene group; ~~or R^8 is C_1-C_6 alkyl;~~ any of which R^8 groups can be optionally mono-, di-, or tri- substituted with R^9, wherein

R^9 is independently selected from the group consisting of halo, oxo, nitrile, azido, nitro, C_1-C_6alkyl, C_0-C_3alkylcarbocyclyl, C_0-C_3alkylheterocyclyl, $NH_2C(=O)$-, Y-NRaRb, Y-O-Rb, Y-C(=O)Rb, Y-(C=O)NRaRb, Y-NRaC(=O)Rb, Y-$NHSO_p$Rb, Y-

$S(=O)_pRb$, Y-$S(=O)_pNRaRb$, Y-C(=O)ORb, Y-NRaC(=O)ORb; wherein said carbocyclyl or heterocyclyl is optionally substituted with R^{10}; wherein

R^{10} is C_1-C_6alkyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, amino, amido, sulfonyl, (C_1-C_3alkyl)sulfonyl, NO_2, OH, SH, halo, haloalkyl, carboxyl;

E is -C(=O)-, -C(=S)-, -$S(=O)_2$-, -S(=O)-, -C(=N-Rf)-;

Rf is H, -CN, -C(=O)NRaRb; -C(=O)C_1-C_3alkyl;

~~X is -NRx- where Rx is H, C_1-C_5alkyl or J; or in the case where E is -C(=O), X can also be -O- or -NRjNRj-;~~

~~wherein one of Rj is H and the other is H, C_1-C_5 alkyl or J;~~

~~R^{11} is H, C_1-C_6alkyl, C_0-C_3alkylcarbocyclyl, C_0-C_3alkylheterocyclyl, any of which can be substituted with halo, oxo, nitrile, azido, nitro, C_1-C_6alkyl, C_0-C_3alkylcarbocyclyl, C_0-C_3alkylheterocyclyl, NH_2C(=O)-, Y-NRaRb, Y-O-Rb, Y-C(=O)Rb, Y-(C=O)NRaRb, Y-NRaC(=O)Rb, Y-$NHSO_p$Rb, Y-$S(=O)_p$Rb, Y-$S(=O)_p$NRaRb, Y-C(=O)ORb, Y-NRaC(=O)ORb; or R^{11} is J;~~

J~~, if present,~~ is a single 3 to 10-membered saturated or partially unsaturated alkylene chain ~~extending~~ that extends from the R^7/$R^{7'}$ cycloalkyl ~~or from the carbon atom to which R^7 is attached~~ to ~~one of Rj, Rx, Ry or R^{11}~~ G ~~to form~~ and forms a macrocycle, which chain is optionally interrupted by one to three heteroatoms independently selected from: -O-, -S- or –NR^{12}-, and wherein 0 to 3 carbon atoms in the chain are optionally substituted with R^{14}; wherein;

R^{12} is H, C_1-C_6alkyl, C_3-C_6cycloalkyl, or C(=O)R^{13};

R^{13} is C_1-C_6alkyl, C_0-C_3alkylcarbocyclyl, C_0-C_3alkylheterocyclyl;

R^{14} is independently selected from the group consisting of H, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, hydroxyl, halo, amino, oxo, thio and C_1-C_6thioalkyl;

~~Ru is independently H or C_1-C_3alkyl;~~

m is 0 ~~or 1~~; n is 0 ~~or 1~~;

~~U is =O or is absent;~~

~~R^{15} is H, C_1-C_6alkyl, C_0-C_3alkylcarbocyclyl, C_0-C_3alkylheterocyclyl, any of which can be substituted with halo, oxo, nitrile, azido, nitro, C_1-C_6 alkyl, C_0-C_3alkylheterocyclyl, C_0-C_3alkylcarbocyclyl, NH_2CO-, Y-NRaRB, Y-O-Rb, Y-C(=O)Rb,~~

~~Y-(C=O)NRaRb, Y-NRaC(=O)Rb, Y-NHSO$_p$Rb, Y-S(=O)$_p$Rb, Y-S(=O)$_p$NRaRb, Y-C(=O)ORb, Y-NRaC(=O)ORb;~~

G is ~~-O-,~~ -NRy-, ~~-NRjNRj-; where one Rj is H and the other Rj is H, C$_1$-C$_5$ alkyl or J;~~

~~Ry is H, C$_1$-C$_3$ alkyl; or~~ Ry is J;

R^{16} is H; or C_1-C_6alkyl, C_0-C_3alkylcarbocyclyl, C_0-C_3alkylheterocyclyl, any of which can be substituted with halo, oxo, nitrile, azido, nitro, C_1-C_6alkyl, C_0-C_3alkylcarbocyclyl, C_0-C_3alkylheterocyclyl, NH_2CO-, Y-NRaRb, Y-O-Rb, Y-C(=O)Rb, Y-(C=O)NRaRb, Y-NRaC(=O)Rb, Y-NHSO$_p$Rb, Y-S(=O)$_p$Rb, Y-S(=O)$_p$NRaRb, Y-C(=O)ORb, Y-NRac(=O)ORb; ~~with the proviso that when m=n=0 and G is O then R^{16} is not tert.butyl or phenyl;~~

or a pharmaceutically acceptable salt thereof.

2. (Canceled)

3. (Currently amended) A compound according to claim 1, with the partial structure [[Ia, Ib or Iaa]] Ia', Ib' or Iaa':





Ia'



Ib'



Iaa'

---

where e is 1 or 2.

4. (Currently amended) A compound <u>according</u> to Claim 1, wherein E is –C(=O)-.

5-7. (Canceled) ~~A compound according to Claim 1, wherein m is 0 and n is 0.~~

8. (Currently Amended) A compound according to Claim [[7]] <u>1</u>, wherein R^{16} is H, C_1-C_3 alkyl or C_3-C_6 cycloalkyl.

9-21 (Canceled).

22. (Withdrawn-currently amended) A compound according to Claim 1, wherein W is –OC(=O)-, -NRa-, [[-NHS(O)$_2$-or]] <u>NHS(O)$_2$-;</u> -NHC(=O)- [[or-]] <u>or</u> -OC(=O)NH-.

23. (Previously presented) A compound according to Claim 1, wherein W is –S-, a bond or –O-.

24. (Currently amended) A compound according to Claim 22 or 23 wherein R^8 is optionally substituted C_0-C_3alkylcarbocyclyl or optionally substituted ~~C_0-C_3-alkylheterocyclyl~~ <u>C_0-C_3-alkylheterocyclyl</u>.

25. (Withdrawn / currently amended) A compound according to Claim 24, wherein the C_0-C_3 alkyl moiety is methylene or ~~preferably~~ a bond.

26. (Withdrawn-currently amended) A compound ~~according to claim 25~~ of formula I':



wherein

A is C(=O)OR[1], or C(=O)NHSO$_2$R[2], wherein;

R[1] is hydrogen, C_1-C_6alkyl, C_0-C_3alkylcarbocyclyl, C_0-C_3alkylheterocyclyl;

R[2] is C_1-C_6alkyl, C_0-C_3alkylcarbocyclyl, C_0-C_3alkylheterocyclyl; wherein

R[2] is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, oxo, nitrile, azido, nitro, C_1-C_6alkyl, C_0-C_3alkylcarbocyclyl, C_0-C_3alkylheterocyclyl, NH_2CO-, Y-NRaRb, Y-O-R_b, Y-C(=O)Rb, Y-(C=O)NRaRb, Y-NRaC(=O)Rb, Y-NHSO$_p$Rb, Y-S(=O)$_p$Rb , Y-S(=O)$_p$NRaRb, Y-C(=O)ORb, Y-NRaC(=O)ORb;

Y is independently a bond or C_1-C_3alkyl;

Ra is independently H or C_1-C_3alkyl;

Rb is independently H, C_1-C_6alkyl, C_0-C_3alkylcarbocyclyl or C_0-C_3alkylheterocyclyl;

p is independenly 1 or 2;

M is CR[7]R[7'];

R[7] taken together with R[7'] forms a C_3-C_6cycloalkyl ring substituted with J;

q is 1 and k is 1;

W is -O-, -OC(=O)NH, -OC(=O), -S-, -NRa, -NHSO$_2$-, –NHC(=O)-, or a bond;

R^8 is C_0-C_3alkylaryl, or C_0-C_3alkylheteroaryl, either of which is optionally mono, di, or tri substituted with R^9, wherein;

R^9 is C_1-C_6 alkyl, C_1-C_6alkoxy, NO_2, OH, halo, trifluoromethyl, amino, amido optionally mono- or di- substituted with C_1-C_6alkyl, C_0-C_3alkylaryl, C_0-C_3alkylheteroaryl, carboxyl, aryl or heteroaryl being optionally substituted with R^{10}; wherein

R^{10} is C_1-C_6alkyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, amino optionally mono- or di-substituted with C_1-C_6alkyl, amido, sulfonylC_1-C_6alkyl, NO_2, OH, halo, trifluoromethyl, carboxyl, or heteroaryl;

E is –C(=O)-, -C(=S)-, -S(=O)$_2$-, -S(=O)-, -C(=N-Rf)-;

Rf is H, -CN, -C(=O)NRaRb; -C(=O)C_1-C_3alkyl;

J is a single 3 to 10-membered saturated or partially unsaturated alkylene chain that extends from the R^7/$R^{7'}$ cycloalkyl to G and forms a macrocycle, which chain is optionally interrupted by one to three heteroatoms independently selected from: -O-, -S- or –NR^{12}-, and wherein 0 to 3 carbon atoms in the chain are optionally substituted with R^{14}; wherein;

R^{12} is H, C_1-C_6alkyl, C_3-C_6cycloalkyl, or C(=O)R^{13};

R^{13} is C_1-C_6alkyl, C_0-C_3alkylcarbocyclyl, C_0-C_3alkylheterocyclyl;

R^{14} is independently selected from the group consisting of H, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, hydroxyl, halo, amino, oxo, thio and C_1-C_6thioalkyl;

m is 0; n is 0;

G is -NRy-;

Ry is J;

R^{16} is H; or C_1-C_6alkyl, C_0-C_3alkylcarbocyclyl, C_0-C_3alkylheterocyclyl, any of which can be substituted with halo, oxo, nitrile, azido, nitro, C_1-C_6alkyl, C_0-C_3alkylcarbocyclyl, C_0-C_3alkylheterocyclyl, NH_2CO-, Y-NRaRb, Y-O-Rb, Y-C(=O)Rb, Y-(C=O)NRaRb, Y-NRaC(=O)Rb, Y-$NHSO_p$Rb, Y-S(=O)$_p$Rb, Y-S(=O)$_p$NRaRb, Y-C(=O)ORb, Y-NRac(=O)ORb;

or a pharmaceutically acceptable salt thereof.

27. (Withdrawn) A compound according to Claim 26 wherein R^9 is C_1-C_6 alkyl, C_1-C_6alkoxy, amino, di-(C_1-C_3 alkyl)amino, C_1-C_3alkylamide, aryl or heteroaryl, the aryl or heteroaryl being optionally substituted with R^{10}; wherein

R^{10} is C_1-C_6alkyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, amino, mono- or di-C_1-C_3alkylamino, amido, halo, trifluoromethyl, or heteroaryl.

28. (Withdrawn) A compound according to Claim 27, wherein R^{10} is C_1-C_6alkyl, C_1-C_6alkoxy, amino optionally mono- or di substituted with C_1-C_3 alkyl, amido, C_1-C_3-alkylamide, halo, or heteroaryl.

29. (Withdrawn) A compound according to Claim 28 wherein R^{10} is methyl, ethyl, isopropyl, tert-butyl, methoxy, chloro, amino optionally mono- or di substituted with C_1-C_3 alkyl, amido, or C_1-C_3alkyl thiazolyl.

30. (Withdrawn) A compound according to Claim 25, wherein R^8 is 1-naphthylmethyl, 2-naphthylmethyl, benzyl, 1-naphthyl, 2-naphthyl, or quinolinyl any of which is unsubstituted, mono, or distributed with R^9.

31. (Withdrawn) A compound according to Claim 30, wherein R^8 is 1-naphthylmethyl, or quinolinyl any of which is unsubstituted, mono, or distributed with R^9.

32. (Withdrawn) A compound according to Claim 31 wherein R^8 is



wherein R^{9a} is C_1-C_6alkyl; C_1-C_6alkoxy; thioC_1-C_3alkyl; amino optionally substituted with C_1-C_6alkyl; C_0-C_3alkylaryl; or C_0-C_3alkylheteroaryl, C_0-C_3alkylheterocyclyl, said aryl, heteroaryl or heterocycle being optionally substituted with R^{10} wherein

R^{10} is C_1-C_6alkyl, C_0-C_3alkylC_3-C_7cycloalkyl, C_1-C_6alkoxy, amino optionally mono- or di-substituted with C1-C6alkyl, amido, C1-C3 amide; and

R^{9b} is C_1-C_6 alkyl, C_1-C_6-alkoxy, amino, di(C_1-C_3alkyl)amino, (C_1-C_3alkyl) amide, NO_2, OH, halo, trifluoromethyl, carboxyl.

33. (Withdrawn) A compound according to Claim 32, wherein R^{9a} is aryl or heteroaryl, either of which is optionally substituted with R^{10}.

34. (Withdrawn) A compound according to Claim 33, wherein R^{9a} is selected from the group consisted of:







wherein R^{10} is H, C_1-C_6alkyl, or C_0-C_3alkylcycloalkyl, amino optionally mono- or di-substituted with C_1-C_6alkyl, amido, (C_1-C_3alkyl)amide.

35. (Withdrawn) A compound according to Claim 33, wherein R^{9a} is phenyl, optionally substituted with C_1-C_6alkyl; C_1-C_6alkoxy; or halo.

36. (Withdrawn) A compound according to Claim 32, wherein R^8 is:



wherein R^{10a} is H, C_1-C_6alkyl, or C_0-C_3alkylcarbocyclyl, amino optinally mono- or di-substituted with C_1-C_6alkyl, amido, heteroaryl or heterocyclyl; and R^{9b} is C_1-C_6 alkyl, C_1-C_6-alkoxy, amino, di(C_1-C_3 alkyl)amino, amide, NO_2, OH, halo, trifluoromethyl, or carboxyl.

37. (Withdrawn) A compound according to Claim 32, wherein R^{9b} is C_1-C_6-alkoxy.

38. (Withdrawn) A compound according to Claim 1, wherein A is $C(=O)NHSO_2R^2$.

39. (Withdrawn) A compound according to Claim 38, wherein R^2 is optionally substituted C_1-C_6 alkyl.

40. (Withdrawn) A compound according to Claim 38, wherein R^2 is optionally substituted C_3-C_7cycloalkyl.

41. (Withdrawn) A compound according to Claim 38, wherein R^2 is optionally substituted C_0-C_6alkylary.

42. (Original) A compound according to Claim 1, wherein A is $C(=O)OR^1$.

43. (Previously presented) A compound according to Claim 42, wherein R^1 is H or C_1-C_6 alkyl.

44. (Cancelled)

45. (Currently amended) A compound according to Claim [[2]], 1 wherein R^7 and [[$R^{7'}$]] R7' together define a spiro-cyclopropyl ~~or spiro-cyclobutyl ring, both optionally mono or di-substituted with R^{7a} wherein; R^{7a} is C_1-C_6 alkyl, C_3-C_5cycloalkyl, or C_2-C_6 alkenyl, any of which is optionally substituted with halo; or R^{7a} is J.~~

46-47. (Canceled)

48. (Currently amended) A compound according to Claim 1, wherein J is a 3 to 8-membered saturated or unsaturated alkylene chain optionally containing one to two heteroatoms independently selected from: -O-, -S- or $-NR^{12}$-, wherein R^{12} is H, C_1-C_6 alkyl, or $-C(=O)C_1$-C_6 alkyl.

49. (original) A compound according to Claim 48, wherein J is a 4 to 7-membered saturated or unsaturated, all carbon alkylene chain.

50. (original) A compound according to Claim 48, wherein J is saturated or mono-unsaturated.

51. (original) A compound according to Claim 48, wherein J is dimensioned to provide a macrocycle of 14 or 15 ring atoms.

52. (original) A pharmaceutical composition comprising a compound as defined in claim 1, and a pharmaceutically acceptable carrier therefor.

53. (original) A pharmaceutical composition according to Claim 52, further comprising an additional HCV antiviral, selected from nucleoside analogue polymerase inhibitors, protease inhibitors, ribavirin and interferon.

54-59. (Canceled)

60. (Currently amended) A compound according to Claim 1 with **[[the]]** formula **[[Ihe]]** Ihe':



Ihe



Ihe'

or pharmaceutically acceptable salt thereof

wherein

R^{16} is H, or C_1-C_6alkyl;

J is a single 3 to 10-membered saturated or partially unsaturated alkylene chain;

q is 1 and k is 1;

A is C(=O)OR^1, or C(=O)$NHSO_2R^2$, wherein

R^1 is hydrogen or C_1-C_6alkyl;

R^2 is C_1-C_6alkyl, C_0-C_3alkylcarbocyclyl, C_0-C_3alkylheterocyclyl;

W is –O- or –OC(=O)NH-;

R^8 is C_0-C_3alkylaryl or C_0-C_3alkylheteroaryl, either of which is optionally mono, di, or tri substituted with R^9, wherein;

R^9 is C_1-C_6alkyl, C_1-C_6alkoxy, NO_2, OH, halo, trifluoromethyl, amino or amido optionally mono- or di-substituted with C_1-C_6alkyl, C_0-C_3alkylaryl, C_0-C_3alkylheteroaryl, carboxyl, said aryl or heteroaryl being optionally substituted with R^{10}; wherein

R^{10} is C_1-C_6alkyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, amino optionally mono- or di-substituted with C_1-C_6alkyl, C_1-C_3 alkyl amide, sulfonylC_1-C_3alkyl, NO_2, OH, halo, trifluoromethyl, carboxyl or heteroaryl.

61. (previously presented) A compound according to Claim 60, wherein J is a single 5-8 membered saturated or partially unsaturated alkylene chain.

62. (previously presented) A compound according to Claims 60, wherein J is monounsaturated.

63. (Currently amended) A compound according to Claim 62, wherein J has one double bond spaced one carbon atom from the cyclopropyl group depicted in the formula [[Ihe]] Ihe'.

64. (previously presented) A compound according to Claim 60, wherein R^8 is the group



wherein R^{9a} is C_0-C_3alkylaryl, C_0-C_3alkylheteroaryl, or C_0-C_3alkylheterocyclyl; said aryl, heteroaryl or heterocyclyl being optionally substituted with R^{10} wherein R^{10} is C_1-C_6alkyl, amino, amino mono- or disubstituted with C_1-C_6alkyl or NHC(=O)C_1-C_6alkyl; and

R^{9b} is C_1-C_6alkoxy; or

R^8 is C_0-C_3alkylaryl wherein the aryl group is optionally substituted with 1-2 substituents selected from C_0-C_3alkylheterocyclyl and trifluoC_1-C_6alkyl; and wherein the C_0-C_3alkylheterocyclyl is optionally substituted with R^{10}.

65. (Previously presented) A compound according to Claim 64, wherein R^{9a} is phenyl,



wherein R^{10} is H, C_1-C_6alkyl, amino, amino mono or disubstituted with C_1-C_3alkyl.

66. (Withdrawn-currently Amended) A compound according to ~~any of Claims~~ Claim 60, wherein A is $C(=O)NHS(=O)_2R^2$.

67. (Withdrawn-currently Amended) A compound according to Claim 66, wherein R^2 is optionally substituted cycloalkyl.

68. (Withdrawn-currently Amended) The compound according to Claim 67 wherein R^2 is optionally substituted cyclopropyl.

69. (New) A compound according to Claim 8, wherein R^{16} is methyl.

70. (New) A compound according to Claim 26, wherein W is -O-.

71. (New) A compound selected from the group consisting of:

19-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-2,16-dioxo-3,15,17-triaza-tricyclo[15.3.0.0*4,6*]icos-7-ene-4,14-dicarboxylic acid 4-ethyl ester 14-methyl ester;

19-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-2,16-dioxo-3,15,17-triaza-tricyclo[15.3.0.0*4,6*]icos-7-ene-3,14-dicarboxylic acid 3-ethyl ester;

14-[(Cyclohexyl-methylcarbamoyl-methyl)-19-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,16-dioxo-3,15,17-triaza-tricyclo[15.3.0.0*4,6*]icos-7-ene-4-carboxylic acid 3-ethyl ester;

14-[(Cyclohexyl-methylcarbamoyl-methyl)-19-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,16-dioxo-3,15,17-triaza-tricyclo[15.3.0.0*4,6*]icos-7-ene-4-carboxylic acid;

[14-Cyclopropanesulfonylaminocarbonyl-17(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,14-dioxo-3,13,15-triaza-tricyclo[13.3.0.0*4,6*]octadec-7-en-13-yl]-carbamic acid ter.butyl ester;

17-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-2,14-dioxo-3,13,15-triaza-tricyclo[13.3.0.0*4,6*]octadec-7-ene-4-carboxylic acid ethyl ester;

17-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-2,14-dioxo-3,13,15-triaza-tricyclo[13.3.0.0*4,6*]octadec-7-ene-4-carboxylic acid;
or a pharmaceutically acceptable salt thereof.

72. (New) A pharmaceutical composition comprising a compound as defined in claim 71, and a pharmaceutically acceptable carrier therefor.

73. (New) A pharmaceutical composition comprising a compound as defined in claim 27, and a pharmaceutically acceptable carrier therefor.